Correction to: Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsNutrition, Genetics, and Disease · Metabolism, Diabetes, and Cancer · RNA modifications and cancer
This is a correction to: Junru Feng, Hui Lu, Wenhao Ma, Wenjing Tian, Zhuan Lu, Hongying Yang, Yongping Cai, Pengfei Cai, Yuchen Sun, Zilong Zhou, Jiaqian Feng, Jiazhong Deng, Ying Shu, Kun Qu, Weidong Jia, Ping Gao, Huafeng Zhang, Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer, Protein & Cell, Volume 13, Issue 11, November 2022, Pages 825–841, https://doi.org/10.1007/s13238-022-00906-6
The Protein & Cell routine checking system detected a duplication in images within Fig. 4C (left panel). After a thorough review of the data files submitted, the authors found that in both the initially submitted version and the revised version, the data were correct. After the manuscript was accepted, in the process of re-formatting the figures, the same image was mistakenly used twice, resulting in an error in the final published version. The corrected figure is shown below.
These details have been corrected only in this correction notice to preserve the published version of record.